Patents Assigned to ELASMOGEN LTD
  • Specific binding molecules
    Patent number: 12371484
    Abstract: The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.
    Type: Grant
    Filed: February 13, 2024
    Date of Patent: July 29, 2025
    Assignee: ELASMOGEN LTD
    Inventors: Obinna Ubah, Caroline Barelle, Andrew Porter
  • FAST-TRACK HUMANISATION OF SPECIFIC BINDING MOLECULES
    Publication number: 20240376639
    Abstract: The present invention relates to a synthetic library of humanised antigen specific binding molecules derived from a member of a species in the Elasmobranchii subclass, processes for the production thereof 5 and specific antigen specific binding molecules isolated from said library. The present invention also relates to the multi-domain specific binding molecules comprising humanised Ig-like Novel Antigen Receptor variable domains (VNARs). Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 14, 2024
    Applicant: ELASMOGEN LTD
    Inventors: Caroline Jane BARELLE, Marina KOVALEVA, Laura Ann FERGUSON, Obinna Chukwuemeka UBAH, Andrew Justin Radcliffe PORTER
  • Fast-track humanisation of specific binding molecules
    Patent number: 12077882
    Abstract: The present invention relates to a synthetic library of humanised antigen specific binding molecules derived from a member of a species in the Elasmobranchii subclass, processes for the production thereof and specific antigen specific binding molecules isolated from said library. The present invention also relates to the multi-domain specific binding molecules comprising humanised Ig-like Novel Antigen Receptor variable domains (VNARs). Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: September 3, 2024
    Assignee: ELASMOGEN LTD
    Inventors: Caroline Jane Barelle, Marina Kovaleva, Laura Ann Ferguson, Obinna Chukwuemeka Ubah, Andrew Justin Radcliffe Porter
  • Specific binding molecules
    Patent number: 11919949
    Abstract: The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 5, 2024
    Assignee: ELASMOGEN LTD
    Inventors: Obinna Ubah, Caroline Barelle, Andrew Porter